Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

Novo Nordisk A/S (NYSE:NVO) shares fell 4.8% to $41.15 in pre-market trading following the release of topline results from Phase 3 trials of its drug Cagrisema. Other notable declines included Aligos Therapeutics Inc (NASDAQ:ALGS) down 15.1% to $4.45, and Telix Pharmaceuticals (NASDAQ:TLX) which dropped 7.9% to $11.60 after announcing a strategic merger agreement with ITM Isotope Technologies Munich SE. Overall, several stocks experienced declines in the pre-market session.